All In MedTech

FDA Clearance Tracker · P180002-S025

Zephyr Endobronchial Valve System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 22, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 22, 2024

Approved

Time to decision

92 days

Received Dec 21, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P180002-S025
Device name
Zephyr Endobronchial Valve System
Applicant location
Redwood City, CA
Received
Dec 21, 2023
Decided
Mar 22, 2024
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P180002

Device type

Device class
Class III

Every decision under product code NJK

FDA's approval statement

As written in FDA's record.

Approval of the labeling supplement as required by the PASR letter issued following the PAS final report P180002/R020.

Source documents

Other decisions for Pulmonx Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.